Valerie Jerdee, MD
Allergy · Brentwood, CANPI 1134145394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 434 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 26.4% of the total. 2025 is the largest year on record at $2,520, 2.7 times the $942 reported in 2019.
Across 434 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$977
- Sanofi$882
- Amgen$609
- Takeda Pharmaceuticals U.S.A., Inc.$405
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$9,72997%
- Education$2553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 120 | $2,641 |
| GSK | 81 | $1,543 |
| Regeneron Healthcare Solutions, Inc. | 29 | $977 |
| Sanofi | 36 | $882 |
| Amgen(2 entities) | 25 | $609 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $405 |
| Kaleo, Inc. | 16 | $354 |
| Novartis | 16 | $340 |
| Optinose US, Inc. | 13 | $283 |
| Pfizer | 13 | $270 |
| Boehringer Ingelheim | 13 | $258 |
| CSL Behring | 8 | $198 |
| Genentech USA, Inc. | 7 | $182 |
| Alk-abello, Inc | 7 | $156 |
| Teva Pharmaceuticals USA, Inc. | 7 | $145 |
| Ionis Pharmaceuticals, Inc. | 4 | $136 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $110 |
| Covis Pharma GmbH | 4 | $110 |
| Grifols USA, LLC | 4 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Pharming Healthcare, Inc. | 2 | $59 |
| Octapharma USA, Inc. | 2 | $51 |
| Phadia US Inc. | 2 | $35 |
| Lilly USA, LLC | 1 | $24 |
| USWM, LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,009 in reported general payments places this provider in the 75th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 29 | $116,175 |
| Dupixent SyringeDupilumab | 16 | $87,078 |
| FasenraBenralizumab | 16 | $83,329 |
| NucalaMepolizumab | 12 | $40,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $31,180 |
| Spiriva RespimatTiotropium Bromide | 25 | $19,647 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $12,379 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 31 | $5,209 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,880 |
| Epinephrine | 23 | $3,863 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,476 |
| Azelastine Hcl | 51 | $1,681 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,640 |
| Montelukast Sodium | 93 | $798 |
| Levocetirizine Dihydrochloride | 41 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Symbicort | $2,641 | $88,20931 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,543 | $83,92972 claims |
| Boehringer IngelheimSpiriva Respimat | $258 | $19,64725 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $145 | $2,47611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 allergy providers in California.
Other allergy in Brentwood
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
- Stuart EpsteinBeverly Hills$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.